Raymond James downgraded Teleflex from Outperform to Mkt Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/4/2025 | $235.00 → $140.00 | Neutral → Underperform | BofA Securities |
| 2/28/2025 | $220.00 → $155.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 2/28/2025 | Outperform → Mkt Perform | Raymond James | |
| 2/28/2025 | $255.00 → $140.00 | Overweight → Neutral | Piper Sandler |
| 2/27/2025 | Mkt Outperform → Mkt Perform | Citizens JMP | |
| 7/1/2024 | $205.00 → $245.00 | Neutral → Overweight | Piper Sandler |
| 12/4/2023 | $261.00 | Equal-Weight → Overweight | Morgan Stanley |
| 6/21/2023 | Buy → Hold | Needham |
WAYNE, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced FDA 510(k) clearance of the AC3 Range™ Intra-Aortic Balloon Pump (IABP). Leveraging the patented technology of the AC3 Optimus™ IABP, the AC3 Range™ IABP is designed to provide reliable, ongoing IABP support across various patient transport modes, including ambulances and both fixed- and rotary-wing aircrafts. The AC3 Range™ IABP combines the simple interface and proprietary algorithms of the AC3 Optimus™ IABP to deliver the same precisely timed support1 with features designed specifically for challenges unique to transport, including a full-s
WAYNE, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that the preliminary results from its Ringer™ PBC IDE study were reported in a featured presentation at the CTO Plus Conference in New York by the study's principal investigator, David E. Kandzari, MD, FACC, MSCAI, Chief, Piedmont Heart Institute and Cardiovascular Services, Chief Scientific Officer and Director, Interventional Cardiology at Piedmont Heart Institute, Atlanta, GA.* Ringer™ PBC is a rapid-exchange percutaneous transluminal coronary angioplasty (PTCA) catheter with a unique helical balloon. When inflated, the balloon approximat
WAYNE, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that new findings from the CLEAR study were presented at the 40th Annual European Association of Urology (EAU) Congress in Madrid, which took place March 21-24, 2025. Among the results, the study showed better early patient satisfaction and sexual function with the UroLift™ System (PUL) compared to Rezūm™ Water Vapor Therapy (WVTT).1 CLEAR is the first head-to-head randomized controlled trial (RCT) comparing early patient outcomes following treatment with UroLift™ PUL and Rezūm™ WVTT, two minimally invasive treatments for the symptoms
SC 13G/A - TELEFLEX INC (0000096943) (Subject)
SC 13G/A - TELEFLEX INC (0000096943) (Subject)
SC 13G/A - TELEFLEX INC (0000096943) (Subject)
BofA Securities downgraded Teleflex from Neutral to Underperform and set a new price target of $140.00 from $235.00 previously
RBC Capital Mkts downgraded Teleflex from Outperform to Sector Perform and set a new price target of $155.00 from $220.00 previously
Raymond James downgraded Teleflex from Outperform to Mkt Perform
DEFA14A - TELEFLEX INC (0000096943) (Filer)
DEF 14A - TELEFLEX INC (0000096943) (Filer)
10-K - TELEFLEX INC (0000096943) (Filer)
WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable March 17, 2025, to shareholders of record at the close of business on March 7, 2025. Additional information about Teleflex can be obtained from the company's website at teleflex.com. About Teleflex IncorporatedAs a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in
WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) (the "Company") today announced financial results for the fourth quarter ended December 31, 2024. Fourth quarter financial summary Revenues of $795.4 million, up 2.8% compared to the prior year period, up 3.2% on an adjusted constant currency basisGAAP diluted EPS from continuing operations of $(2.95), compared to $0.66 in the prior year periodAdjusted diluted EPS from continuing operations of $3.89, compared to $3.38 in the prior year period Full year 2024 financial summary GAAP revenue of $3,047.3 million, up 2.4% compared to the prior year periodAdjusted revenue of $3,061.1 million, excluding the impact f
Teleflex to create a new, independent publicly traded company ("NewCo") consisting of Teleflex's Urology, Acute Care, and OEM businesses.Teleflex RemainCo ("RemainCo") will consist of Teleflex's Vascular Access, Interventional, and Surgical businesses – focusing on high-growth, high-acuity, primarily hospital-focused emergent end markets.Separation expected to position RemainCo to deliver 6%+ constant currency revenue growth post-separation, to be accretive to Teleflex adjusted gross margin, initially neutral to Teleflex adjusted operating margin, and drive double-digit EPS growth in the first full year post separation.Separation will position each company to accelerate its growth profile wi
4 - TELEFLEX INC (0000096943) (Issuer)
4 - TELEFLEX INC (0000096943) (Issuer)
4 - TELEFLEX INC (0000096943) (Issuer)
NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P
Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With
WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that Thomas E. Powell, Teleflex's Chief Financial Officer, has decided to retire as Executive Vice President and Chief Financial Officer, effective April 1, 2025. John R. Deren, who currently serves as Corporate Vice President and Chief Accounting Officer of Teleflex, will succeed Mr. Powell as Executive Vice President and Chief Financial Officer, effective April 2, 2025. Following his retirement, Mr. Powell will serve as a consultant to the company through March 31, 2026 to support continuity and a smooth transition. "Tom has announced his des